Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Breast cancer

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Feb 03, 2021 2:03pm

73 Views

Post# 32460160

RE:RE:RE:Breast cancer

It's proving the drug actually interferes with that process is what is required.

scarlet1967 wrote:

“Progranulin and one of its signaling receptors sortilin have previously been shown to be involved in cancer stem cell propagation and in metastasis formation.

Taken together, these results demonstrated that progranulin increased cell secretion of many proteins, several of them dependent on sortilin binding. It has previously been shown that progranulin increase metastasis formation via sortilin, but here we also show a progranulin-dependent increase of secreted proteins such as CXCL1, IL-6 and IL-8, which also have been shown to be involved in metastasis and priming of the pre-metastatic niche, suggesting an additive overall increased risk for metastasis with high progranulin levels. Inhibiting the binding of progranulin and IL-6 to sortilin could potentially decrease cancer stem cells and reduce metastasis. A sortilin targeted therapy in combination with existing therapies could potentially be beneficial for breast cancer patients.”

qwerty22 wrote:
It really doesn't take much to show if THTX's drug has an inhibitory effect of this progranulin/sortilin mechanism. Basically all you need to do is repeat the expt the Swede's did but replace the sortilin inhibitor with THTTX's drug and see if you get the same outcome, maybe throw in a few more controls as well like THTX's peptide-alone and docetaxel-alone but you get an answer to whether the drug just hitches a ride on Sortilin to deliver it chemo bomb or also disrupts it. If the Swede's where amenable I'd contract them to do the work.

This is not quite genomics but there would be a lot to be learned to see what is going on at the molecular level when you expose cancer cells to THTX's drug.

Another plea to THTX : Plz give me a second MOA for the cancer drug.

scarlet1967 wrote: Spartrap just posted this research study from university of Gothenburg in Sweden published recently.
Read page 40!
https://gupea.ub.gu.se/bitstream/2077/66821/2/gupea_2077_66821_2.pdf